PMID- 31714902
OWN - NLM
STAT- MEDLINE
DCOM- 20200327
LR  - 20211204
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 25
DP  - 2019 Nov 12
TI  - Eriocalyxin B Induces Apoptosis and Autophagy Involving Akt/Mammalian Target of 
      Rapamycin (mTOR) Pathway in Prostate Cancer Cells.
PG  - 8534-8543
LID - 10.12659/MSM.917333 [doi]
AB  - BACKGROUND Eriocalyxin B (EriB), a diterpenoid isolated from the plant Isodon 
      eriocalyx, has been shown to possess anti-tumor properties. However, few 
      systematic studies of the mechanism underlying the anti-tumor activity of 
      Eriocalyxin B in prostate cancer cells have been published. The aim of this study 
      was to investigate the effect of Eriocalyxin B on prostate cancer cells. MATERIAL 
      AND METHODS In the present study, the PC-3 (androgen-independent) and 22RV1 
      (androgen-dependent) human prostate cancer cell lines were cultured with and 
      without increasing doses of Eriocalyxin B. MTT assay was used to measure cell 
      viability. Western blotting was performed to measure levels of proteins 
      associated with apoptosis and autophagy. Flow cytometry was used to assess 
      changes in cell apoptosis and cycle. Fluorescence microscopy was used to capture 
      images of autophagy-related proteins. RESULTS Treatment of human prostate cancer 
      cells with Eriocalyxin B resulted in apoptosis in a dose- and time-dependent 
      manner. Eriocalyxin B also induced autophagy, with elevated LC3B-II protein 
      expression and punctuate patterns. Additionally, autophagy protected prostate 
      cancer cells from apoptosis induced by Eriocalyxin B, which was demonstrated by 
      addition of chloroquine (CQ). Moreover, the results indicated that Eriocalyxin B 
      could inhibit the phosphorylation of Akt and mTOR. Eriocalyxin B induced 
      apoptosis and autophagy by inhibition of the Akt/mTOR pathway. CONCLUSIONS 
      Eriocalyxin B induces apoptosis and autophagy involving the Akt/mTOR pathway in 
      prostate cancer cells in vitro. These findings provide evidence for Eriocalyxin B 
      as a potent therapeutic for the treatment of prostate cancer.
FAU - Yu, Ziqiang
AU  - Yu Z
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui, China (mainland).
AD  - Institute of Urology, Anhui Medical University, Hefei, Anhui, China (mainland).
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, Anhui, China (mainland).
FAU - Chen, Yang
AU  - Chen Y
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui, China (mainland).
AD  - Institute of Urology, Anhui Medical University, Hefei, Anhui, China (mainland).
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, Anhui, China (mainland).
FAU - Liang, Chaozhao
AU  - Liang C
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui, China (mainland).
AD  - Institute of Urology, Anhui Medical University, Hefei, Anhui, China (mainland).
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, Anhui, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20191112
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Diterpenes)
RN  - 0 (eriocalyxin B)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - China
MH  - Diterpenes/*metabolism/*pharmacology
MH  - Humans
MH  - Male
MH  - PC-3 Cells
MH  - Prostate/metabolism
MH  - Prostatic Neoplasms/*metabolism/pathology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC6873644
COIS- Conflict of interest None.
EDAT- 2019/11/13 06:00
MHDA- 2020/03/28 06:00
PMCR- 2019/11/12
CRDT- 2019/11/13 06:00
PHST- 2019/11/13 06:00 [entrez]
PHST- 2019/11/13 06:00 [pubmed]
PHST- 2020/03/28 06:00 [medline]
PHST- 2019/11/12 00:00 [pmc-release]
AID - 917333 [pii]
AID - 10.12659/MSM.917333 [doi]
PST - epublish
SO  - Med Sci Monit. 2019 Nov 12;25:8534-8543. doi: 10.12659/MSM.917333.